BMS-650032
BMS-650032 is a pharmaceutical drug with 8 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
8 of 8 finished
0.0%
0 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
Clinical Trials (8)
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
Drug Interaction Oral Contraceptive Pill (OCP)
Drug-Drug Interaction Study in Healthy Subjects
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8